Biomoda to Optimize CyPath Diagnostic Assay

Biomoda (OTCBB: BMOD), having completed enrollment for its pilot clinical study, seeks to optimize its assay and to automate the process for reading CyPath®-labeled cells.  In so doing, the Company will benefit from lower costs and greater accuracy in a high-throughput clinical setting.  In addition, Biomoda’s ongoing research, both independently and in partnership with other scientific and medical institutions, is focused on improving methods for the non-invasive collection of sputum samples and refining the use of fluorescent microscopy to identify cancer and pre-cancerous cells.

Read More

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: